ERBB2 and neoplasm: Overall, breast cancer, particularly the ER+ HER2− sub-group, due to the relatively low rate of tumor-infiltrating lymphocytes (TILs) in the tumor microenvironment (TME), is considered scarcely or moderately immunogenic.